Preoperative Skin Conditioning: Extracellular Matrix Clearance and Skin Bed Preparation, A New Paradigm. by Widgerow, Alan D et al.
UC Irvine
UC Irvine Previously Published Works
Title
Preoperative Skin Conditioning: Extracellular Matrix Clearance and Skin Bed Preparation, A 
New Paradigm.
Permalink
https://escholarship.org/uc/item/51x661mq
Journal
Aesthetic surgery journal, 39(Suppl_3)
ISSN
1090-820X
Authors
Widgerow, Alan D
Cohen, Steven R
Fagien, Steven
Publication Date
2019-04-01
DOI
10.1093/asj/sjz022
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Supplement
DOI: 10.1093/asj/sjz022
www.aestheticsurgeryjournal.com
© 2019 The American Society 
for Aesthetic Plastic Surgery, Inc. 
This is an Open Access article 
distributed under the terms of the 
Creative Commons Attribution 
Non-Commercial License (http://
creativecommons.org/licenses/
by-nc/4.0/), which permits 
non-commercial re-use, distri-
bution, and reproduction in any 
medium, provided the original 
work is properly cited. For com-
mercial re-use, please contact 
journals.permissions@oup.com
Aesthetic Surgery Journal
2019, Vol 39(S3) S103–S111Preoperative Skin Conditioning: Extracellular 
Matrix Clearance and Skin Bed Preparation, 
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Steven R. Cohen, MD, FACS; and Steven Fagien, MD, FACS
Abstract
This paper introduces the concept of “skin bed preparation” prior to surgical procedures. Following the theory of chronic wound bed preparation 
and adapting the skin model to one of chronic wound changes related to extrinsic and intrinsic factors, a topical formulation aimed at recycling the 
extracellular matrix (ECM) from accumulated waste products is evaluated and discussed. The clearance of these products and stimulation of new 
replacements has the potential to change the regenerative milieu of the skin so that when procedures are carried out, cellular signaling and cross-talk 
at the dermal level are improved and healing is optimized. By introducing a combination of peptides and other synergistic active agents, a sequence 
of clearance, regeneration, and remodeling is initiated. This is confirmed and validated by a series of biopsies and clinical studies that demonstrate 
changes in the ECM as early as 2 to 3 weeks after application. Clinical studies related to resurfacing procedures show accelerated healing and improved 
symptomatic relief compared with standard of care by preconditioning the skin 2 weeks prior to the procedure. A similar approach is suggested as a 
potential advantage for invasive surgical procedures based on similar scientific principles elucidated on in the text.
Editorial Decision date: January 15, 2019.
The concept of prepping the canvas prior to surgery is not 
a new one. Plastic surgeons and dermatologists have uti-
lized various techniques and agents prior to surgery, as 
well as treatment with laser/energy-based devices, in an 
attempt to influence the surgical outcome or final result. 
Whether the aim was to improve vascularity (ie, the delay 
phenomenon), influence pigmentation, or simply use oral 
supplements to improve immunity, the ultimate goal was 
to optimize the healing process. In recent years major 
strides have been made in our understanding and knowl-
edge of the field of wound healing.
In particular, chronic wound management is gov-
erned by a set of principles that prepare the wound 
bed for healing prior to applying any therapeutics. 
This was deemed necessary as the accumulation of 
by-products from dysfunctional healing and excess 
inflammation created a wound bed milieu that obviated 
healing. Ridding the wound bed of these by-products 
thus became a priority in wound bed preparation. The 
preparation took the form of wound debridement, con-
trolled inflammation, adequate moisture, and a host of 
techniques to encourage epithelialization—ie, the DIME 
principles,  which were aimed at accelerating endoge-
nous healing or facilitating the effectiveness of thera-
peutic measures.1
Advancing this concept and theory, and the principles 
to skin homeostasis, is a logical progression. When one 
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considers that skin has been subjected to years of extrin-
sically induced degradation mainly in the form of pho-
todamage, coupled with intrinsic changes brought about 
by aging, the similarity with the chronic wound model 
becomes apparent. Much the same as chronic wounds 
accumulate the by-products noted above, so the skin, in 
particular the extracellular matrix (ECM), accumulates 
waste products that hinder cellular and protein cross-talk 
and signaling, the very signaling that is paramount in nor-
mal wound healing.
The clearance of these products and stimulation of new 
replacements has the potential to change the regenerative 
milieu of the skin so that when procedures are carried out, 
cellular signaling and cross-talk at the dermal level are 
improved and healing is optimized.
ECM Changes Defined
When viewing the skin in terms of the “chronic wound” 
paradigm it is necessary to first define the molecular 
changes occurring in the dermal (and to a lesser degree 
epidermal) layers. The ECM is the central orchestrator 
of communication between cells and a multitude of 
proteins. Changes within the matrix dictate outcomes 
in cellular function and protein production. Aging and 
photodamage directly affect these essential functions, 
creating inefficient communication between the 
constituents of the ECM. This ongoing conversation 
should continue uninterrupted to ensure healthy skin 
maintenance and renewal, but breakdown products 
tend to accumulate and disrupt communication in the 
following ways:
 • Photodamage causes cells to release enzymes (eg, 
MMP-1-collagenase) that fragment type 1 collagen from 
long healthy strands. These smaller collagen fragments 
prevent the fibroblast from “stretching out” its healthy 
spindle shape along the course of the fiber, resulting in 
a change of shape to a rounded fibroblast2
 • A rounded fibroblast is a senescent, inefficient fibroblast 
that produces limited amounts of collagen and elastin, 
impeding regeneration3
 • Acute bursts of sun exposure cause white blood cells 
to release neutrophil elastase, affecting the quality 
of existing elastin fibers, and breaking down fibrillin 
components3,4
 • The fragments of collagen that remain, known as gela-
tin, adhere to the elastin fragments, causing an aggluti-
nation of gelatinous clumps that interferes with normal 
ECM communication3
 • Intrinsic aging also results in accumulation of wear-and-
tear waste products—intracellular protein fragments 
and glycation end products5
The dermis and the ECM is now filled with fragmented 
sticky clumps of collagen and elastin and the fibroblasts 
are senescent and unproductive. The epidermis is thinned 
and wrinkled, barrier protection is affected, and elasticity 
is diminished (Figure 1). This is normally the status of the 
skin prior to surgical intervention. What if the status could 
be changed and in a short period of time, a matter of weeks, 
the senescent milieu of the ECM could be transformed into 
a regenerative one? Would that not facilitate healing and 
outcomes irrespective of the procedure? This is skin bed 
preparation.
A key differentiator with TriHex Technology (ALASTIN 
Skincare, Inc., Carlsbad, CA) is its proprietary recycling 
mechanism to help remove aged, damaged fragments and 
restore the optimal environment for new, healthy collagen 
and elastin.
Effecting ECM Changes: Skin Bed 
Preparation
Analogous to wound bed preparation before therapeutic 
intervention for chronic wounds, “skin bed preparation” aims 
to optimize rejuvenation procedures and skin maintenance 
programs. This involves introducing agents that can combat 
stress-induced oxidation, proteasome dysfunction, and 
nonenzymatic cross-linkages involved in glycation end 
products, to collectively modulate this damaged ECM, and 
upregulate neocollagenesis and elastin production. Agents of 
particular interest are matrikines, peptides originating from 
Figure 1. Chronic sun damage and aging results in 
fragmented collagen, elastin, and senescent rounded 
fibroblasts in the ECM and thinned epidermal layer. ECM, 
extracellular matrix.
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the fragmentation of matrix proteins, which exhibit a wide 
range of biological activities relating to matrix modulation.6 
Peptides of this type (tripeptides and hexapeptides) are 
incorporated in TriHex Technology, which is designed to 
target ECM modulation with the goal of optimizing results 
following invasive and noninvasive dermal rejuvenating 
procedures. Additionally, oleuropein (a lipoxygenase 
activity inhibitor) and phosphatidylserine (a signal enzyme 
activator) are included in the TriHex Technology formulation 
to decrease inflammation and stimulate cellular recycling of 
waste products.
From the aspect of matrix degradation and restructur-
ing described above, a sequence of targeted approaches to 
repair and regenerate the ECM includes the following:
 • “Mopping-up” of excess collagen and elastin fragments 
in the ECM with balanced MMP production (MMP2- 
also known as gelatinase enzyme release)
 • Combating oxidative stress via reactive oxygen species 
end products generated in the ECM
 • Stimulation of procollagen and collagen, thereby 
increasing lysyl oxidase beneficial cross-linkages and 
improving fiber alignment
 • Stimulating elastin (particularly fibrillin) to regenerate 
ECM elasticity
 • Increasing the efficiency of the proteasome system by 
eliminating dysfunctional proteins
 • Reducing the destruction of normal collagen fragments 
by MMP-1
 • Decreasing glycation end products
The select peptides and botanical extracts synergistically 
and sequentially aid in this ECM modulation to optimize 
and “prime” the skin for rejuvenating procedures 
(Figure 2).
Validating ECM Changes
The scientific narrative for skin bed preparation is a logical 
approach to consider prior to surgery if the skin is to be 
considered as akin to a chronic wound. However, validation 
of the narrative is imperative. First, in vitro testing of 
components and of the formulation itself was undertaken 
and expression of the genes involved in ECM remodeling 
was confirmed.7 Second, histologic examination of 5 
subjects in their 60s was undertaken, assessing changes 
related to isolated topical application of product to the 
skin. The aim was to ascertain—from punch biopsy and 
examination of excision specimens—if topical application 
of product alone could initiate histologic changes in a short 
period of time.8 For each specimen, representative high-
power fields of the superficial dermis and deep dermis were 
evaluated. The amount of collagen within the high-power 
field was quantified as a percentage of the total dermal 
ECM. In a similar manner, Verhoeff-Van Gieson (VVG) 
staining of elastic fibers was evaluated as a percentage of 
the connective tissue within a representative high-power 
field from both the superficial dermis and deep dermis. 
Overall, biopsy results revealed significant changes within 
the ECM in all subjects tested, who showed new collagen 
formation, increased elastin, a “healthier” epidermis with 
more cuboidal basal stem cells at the dermo-epidermal 
junction, and a thickened epidermis (Figures 3-5).8
Finally, clinical trials assessing the differences in 
patients preconditioned with the product versus standard 
of care were undertaken in a number of centers, with var-
ied devices, procedures, and anatomic sites.9-11 In one trial 
under institutional review board (Chesapeake) supervi-
sion, 15 patients were evaluated after treatment with the 
product following fractionated CO2 laser resurfacing, and 
compared to treatment with a bland ointment and cream. 
A blinded investigator graded erythema, edema, crusting, 
exudation, and healing on postprocedure days 1, 3, 4, 7, 
28, and 84. A photodamage/wrinkle scale was completed 
on days 28 and 84. Subjects performed symptomatology 
grading on days 1 to 14 and completed self-assessments 
at days 28 and 84. Data from 14 subjects were analyzed. 
Blinded-investigator-rated healing was better for the 
TriHex Technology system, reaching statistical significance 
at day 7.  The TriHex group demonstrated less erythema 
and exudation during the first postprocedure week, reach-
ing significance on day 3. On days 1 to 14, subjects treated 
with the test product reported less tenderness and burn-
ing/stinging, also reaching significance on day 3. On day 
84, subjects treated with the TriHex system reported higher 
Figure 2. “Recycled” matrix where fragmented collagen and 
elastin have been replaced by new long-strand structural 
proteins, spindle-shaped active fibroblasts, a healthy basal 
stem cell layer, and a thickened epidermis.
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satisfaction and were more likely to recommend the treat-
ment to others (Figures 6 and 7).9
In a split face study with the same product and proto-
col following fractional nonablative thulium-doped resur-
facing treatment of the face or décolleté, the test product 
was found to be statistically superior to the basic regimen 
following laser treatment from day 4 based on healing, 
lentigines, texture, and global skin quality. Subjects also 
reported “better looking and feeling” skin on the test side. 
It was concluded that preconditioning with the TriHex test 
product improved healing post-nonablative thulium-doped 
resurfacing treatment to the face/décolleté in comparison 
with standard of care.10
Thus, in cases involving resurfacing of the face, pre-
conditioning with TriHex Technology appears to speed 
up healing, and decrease redness, swelling, burning, and 
stinging; patients enjoy applying the treatment and feel it 
improves long-term outcome. No adverse events related to 
product use were reported in any of the studies referred 
to above.
The question now remains: how would precondition-
ing affect more invasive surgical procedures? To that end 
patients undergoing full face lift or upper blepharoplasties 
were selected. One side was pretreated for 2 to 4 weeks 
prior to surgery and specimens from both sides were sub-
mitted for histology at the time of the procedure. In the 
first 5 patients tested, biopsy results revealed increased 
collagen staining with healthier ECM and diminished solar 
elastosis (Figures 8 and 9).
Limitations
Much of this scientific narrative is based on a working 
hypothesis that the documented histologic molecular 
A B
Figure 3. H&E staining (100×) showing ECM and epidermal changes following a 3-week topical application of product 
containing TriHex Technology peptides and botanicals to the forearm (65-year-old female patient). (A) Baseline H&E-stained 
sections from nontreated forearm skin shows thicker, mature collagen bundles, and thinner epidermis with flattened basal 
cells. (B) Post-treatment (right), the epidermis shows less atrophy, with increased number of layers, more cuboidal basal cells, 
and recovery of normal epidermal maturation. The ECM shows finer collagen bundles, likely representing neocollagenesis. 
This is a low-powered representation that clearly shows a good distribution of newer fresh collagen well spread over the 
entire frame of the ECM as opposed to the mature older collagen apparent in the baseline ECM of the slide in panel A. ECM, 
extracellular matrix; H&E, hematoxylin and eosin.
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Figure 4. H&E-stained sections (200×) from biopsies taken at baseline (left) and following a 3-week (right) topical application 
of TriHex Technology peptide gel to the preauricular region (62-year-old male patient). (A) Baseline H&E-stained sections from 
nontreated preauricular skin shows limited collagen in the upper dermis and basophilic solar elastotic changes in the dermal 
ECM. (B) Post topical treatment, there is less epidermal atrophy, with recovery of normal epidermal maturation. In the dermis, 
newly formed (pink) collagen is present, replacing some of the severe solar elastosis. An increased number of fibroblasts 
is easily identified among the newly formed ECM in the papillary dermis. Multiple views of these slides demonstrated 5% 
content of superficial collagen in baseline (A) vs 30% content of superficial collagen after 3 weeks (6-fold increase). ECM, 
extracellular matrix; H&E, hematoxylin and eosin.
A B
Figure 5. Elastin immunohistochemical staining of sections from biopsies taken at baseline and following a 3-week topical 
application of the TriHex Technology product to the forearm (63-year-old male patient) (100×) [Abcam anti-elastin mouse 
monoclonal antibody (BA-4), 1:100 dilution]. (A) Baseline shows minimal elastin staining in the dermis. (B) Post topical 
treatment, there is a striking increase in the amount of dermal elastin staining. This is a low-powered magnification which 
gives a good overall view; assessment of the complete slide confirmed 10% elastic fiber in superficial layers vs 90% elastin 
content in superficial dermis (extending to deep dermis) after treatment.
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Figure 6. Baseline prior to treatment. (A) A 53-year-old female received TriHex Technology pretreatment and follow-up 
treatment. (B) Day 1 following moderately deep ablative resurfacing. (C) Day 4 following treatment showing good 
epithelialization and advanced healing. (D) Day 7 following treatment showing complete healing; able to apply cosmetics.
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Figure 7. Baseline prior to treatment. (A) A 54-year-old female received (Vaniply, Pharmaceutical Specialties, Inc., Rochester, 
MN, USA) pretreatment and follow-up treatment. (B) Day 1 following moderately deep ablative resurfacing. (C) Day 4 
following treatment showing minimal epithelialization and healing compared with the experimental group; day 4 is the day 
where the most obvious difference between groups was evident. (D) Day 7 following treatment showing some unresolved 
healing and more redness than comparator.
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Figure 9. Eyelid specimens post upper blepharoplasty (47-year-old female patient, H&E staining, 100×). (A) Left eyelid 
specimen; no treatment prior to procedure showing extensive solar elastosis and minimal collagen in the dermis. (B) Right 
eyelid specimen following a 4-week pretreatment showing improved solar elastosis and increased collagen production. There 
are well-demonstrated changes in this slide; quantitative reassessment showed a superficial collagen content of 40% on 
the nontreated side (A) vs a 90% content of superficial collagen on the treated side as well as significantly improved solar 
elastosis. H&E, hematoxylin and eosin.
A B
Figure 8. Elastin VVG staining 200× (58-year-old female patient). (A) Left side the of the face received no pretreatment; 
elastin staining evident. (B) Right side following 2 weeks of pretreatment demonstrating increased elastic fiber in the dermis 
with more prominent and deeper elastin staining. Overall multiview assessment demonstrated 10% elastin content in the 
superficial dermis and deep dermis on the untreated side vs 20% and 25%, respectively, on the treated side (at least a 
2-fold increase plus changes in the nature of the fibers—fragmented smaller fibers untreated, more solid longer fibers after 
treatment). VVG, Verhoeff-Van Gieson.
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changes seen in many cases following topical application 
may be beneficial to surgical outcomes by changing the 
nature of the ECM and thus the potential for improved cell 
to cell and cell to matrix cross-talk. The limitations here 
are small numbers and limited data related to the clinical 
studies and biopsies presented; however, all preliminary 
findings do appear to indicate healing advantages and 
symptomatic relief related to the preconditioning. More 
work is definitely required to validate this concept, but this 
is in keeping with the introduction of a new “hot topic” 
concept.
CONCLUSIONS
This concept of preparing skin and its molecular 
complexities for surgery has a sound scientific basis. The 
final outcome of all surgeries, especially those with aesthetic 
objectives, relies on optimized healing and scarring. To 
that end previous work has demonstrated that controlled 
inflammation, adequate hydration, and an accelerated 
healing process all contribute to good scar outcomes.12,13 
Additionally, we have shown in our resurfacing cases that 
redness, exudate, burning, and stinging can be reduced 
by preconditioning, but perhaps more importantly, that 
healing can be hastened. Taking these data and expanding 
them to objectively assess outcomes following more 
complex surgical procedures is a natural next step in 
the process. The foundation  for  pursuing this endeavor 
appears to be well established.
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